Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potency ratio--a brief synopsis

L V Avioli1

  • 1Division of Endocrinology, Jewish Hospital of St Louis, MO 63110.

British Journal of Rheumatology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Deflazacort (DFZ) offers bone-sparing advantages over prednisone (PDN). Studies show DFZ is more potent and causes significantly less bone loss than PDN at equivalent therapeutic doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro andIn Vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene.

Calcified tissue international·2016
Same author

Ethical guidelines for publication of research.

Calcified tissue international·2016
Same author

Salmon calcitonin nasal spray : An effective alternative to estrogen therapy in select postmenopausal women.

Endocrine·2010
Same author

In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene.

Calcified tissue international·2001
Same author

Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells.

The Journal of biological chemistry·2001
Same author

Bone mineralization and osteoblast differentiation are negatively modulated by integrin alpha(v)beta3.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2001

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Metabolism

Background:

  • Glucocorticoids are widely used but associated with bone loss.
  • Deflazacort (DFZ) is a novel glucocorticoid with reported bone-sparing properties.
  • Comparing glucocorticoid potency and bone-wasting effects is crucial for clinical use.

Purpose of the Study:

  • To evaluate the potency of deflazacort (DFZ) relative to prednisone (PDN) and methylprednisolone.
  • To assess the bone-wasting properties of DFZ compared to PDN using the bone wasting ratio.

Main Methods:

  • Potency was established using double-blind, crossover, paired, and between-patient studies.
  • Minimum effective doses were determined for potency and bone loss comparisons.
  • Bone wasting ratio was calculated from bone loss velocity values at equivalent therapeutic doses.

Related Experiment Videos

Main Results:

  • Deflazacort (DFZ) is 1.28 times more potent than prednisone (PDN) and 1.6 times more potent than methylprednisolone.
  • The bone wasting ratio of PDN to DFZ is approximately 2.03:1.
  • At equivalent doses, prednisone (PDN) causes twice as much bone loss as deflazacort (DFZ).

Conclusions:

  • Deflazacort (DFZ) demonstrates superior potency and significantly reduced bone-wasting properties compared to prednisone (PDN).
  • These findings highlight the potential clinical benefit of DFZ in minimizing glucocorticoid-induced bone loss.